Trimethoprim

證據等級: L5

預測適應症: 2 個

Trimethoprim: From Bacterial Infections to Conjunctivitis

One-Sentence Summary

Trimethoprim is a dihydrofolate reductase (DHFR) inhibitor classically used against bacterial infections (e.g. urinary tract infections), typically as part of a combination product. The TxGNN model predicts it may be effective for Conjunctivitis (bacterial), with 3 clinical trials and 20 publications currently identified, including a completed Phase 4 head-to-head RCT against moxifloxacin. This is less a novel discovery than confirmation of an already-established use: trimethoprim/polymyxin B (Polytrim) is a marketed ophthalmic antibiotic elsewhere, though trimethoprim itself is not currently licensed in New Zealand.

Quick Overview

Item	Content
Original Indication	Not on file — trimethoprim has no New Zealand license, so no approved indication text exists; known pharmacological use is bacterial infections (e.g. UTIs)
Predicted New Indication	Conjunctivitis (bacterial)
TxGNN Prediction Score	99.17%
Evidence Level	L1
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not on file for this drug record (flagged as a High-severity data gap). Based on known pharmacology captured in the evidence pack, trimethoprim inhibits bacterial dihydrofolate reductase (DHFR), blocking folate synthesis and producing bacteriostatic/bactericidal activity against common conjunctivitis pathogens such as Haemophilus influenzae and Streptococcus pneumoniae.

Critically, this prediction is not really a new hypothesis — trimethoprim/polymyxin B (marketed as Polytrim) is already an approved topical antibiotic for bacterial conjunctivitis in multiple jurisdictions. TxGNN's high score reflects a known, mechanistically direct relationship rather than a speculative repositioning. The caveat is specificity: trimethoprim's mechanism only supports bacterial conjunctivitis — it has no activity against viral or chlamydial causes (standard therapy for neonatal chlamydial conjunctivitis is macrolide-based, not trimethoprim, per PMID 30007329).

Note: TxGNN also flagged punctate epithelial keratoconjunctivitis (score 99.57%) as a top candidate, but this was excluded from further evaluation (Evidence Level L5, decision Hold) — no clinical trials or literature support it, and the condition's predominantly viral/immune-mediated etiology has no clear mechanistic link to trimethoprim's antibacterial action.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00581542	Phase 4	Completed	124	Head-to-head comparison of Polytrim (trimethoprim/polymyxin B) vs. moxifloxacin ophthalmic solution for pediatric conjunctivitis ("pink eye")
NCT03187834	Phase 4	Completed	252	Antibiotic resistance/microbiome study in children (Burkina Faso); background antibiotic-exposure research, not a conjunctivitis efficacy trial
NCT00168532	Phase 3	Completed	218	Community RCT of prophylactic antibiotics in measles infection (Guinea-Bissau); conjunctivitis is only an incidental complication, not the primary treatment target

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30007329	2018	Systematic Review/Meta-analysis	J Pediatr Infect Dis Soc	Reviewed antibiotic treatments (including trimethoprim) for neonatal chlamydial conjunctivitis; macrolides remain standard, trimethoprim not preferred for this etiology
19043945	2008	RCT	J Pediatr Ophthalmol Strabismus	Multicenter trial comparing speed of clinical efficacy of polymyxin B/trimethoprim vs. 0.5% moxifloxacin in bacterial conjunctivitis
8595639	1995	Cohort/Case series	Clinical Therapeutics	Survey of children with acute bacterial conjunctivitis treated with trimethoprim-polymyxin B ophthalmic solution
6204534	1984	Clinical evaluation	Am J Ophthalmol	Early clinical evaluation of trimethoprim-containing ophthalmic solutions (with sulfacetamide or polymyxin B) for bacterial conjunctivitis/blepharitis
16491721	2006	Review	J Pediatr Ophthalmol Strabismus	Guidance on controlling contagious bacterial conjunctivitis outbreaks with antimicrobial therapy
20084257	2001	Review	Paediatr Child Health	Review of etiology, features, and management of acute infectious conjunctivitis in children
10537781	1999	Review	Curr Opin Ophthalmol	Overview of ocular manifestations of cat-scratch disease (differential diagnosis context)
8924168	1996	Review	Laryngo-Rhino-Otologie	Overview of cat-scratch disease for ENT physicians (differential diagnosis context)
24892274	2015	Case report	Ophthalmic Plast Reconstr Surg	Case of chronic Nocardia-related conjunctivitis on a silicone stent, sensitive to trimethoprim/sulfamethoxazole
19913370	2010	Case report	Vet Microbiol	Veterinary case series (equine conjunctivitis pathogens); limited direct relevance to human use

Safety Considerations

Please refer to the package insert for safety information. Note that TFDA/NZ package insert warnings and contraindications for this drug are currently a Blocking data gap — this must be resolved before a formal S1 safety review can proceed.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Bacterial conjunctivitis as an indication is well supported — a completed Phase 4 head-to-head RCT (NCT00581542) plus several decades of consistent RCT, cohort, and clinical-evaluation literature show trimethoprim/polymyxin B performing comparably to standard antibiotics such as moxifloxacin. However, trimethoprim has no current New Zealand market authorization and no on-file safety/warning data, so guardrails are needed before this evidence can translate into a local decision.

To proceed, the following is needed:

TFDA/NZ package insert warnings and contraindications (Blocking gap — required before S1 safety review)
Confirmed mechanism-of-action data from DrugBank (High-severity gap)
A regulatory pathway assessment for New Zealand licensing (currently 0 authorizations)
Updated resistance-pattern literature, since most supporting evidence dates from 1984–2018
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.